PMV Pharma reports FY2024 net loss of $58.7M; cash runway to end of 2026; Phase 2 interim data mid-2025

PMV Pharmaceuticals, Inc.

Net loss of $58.7M for FY2024, compared to $69.0M in FY2023; no revenue.
Cash, cash equivalents & marketable securities of $183.3M as of Dec 31, 2024; provides cash runway to end of 2026.
Phase 2 PYNNACLE trial enrollment on track; interim analysis data expected mid-2025; NDA submission anticipated by end of 2026.
Discontinued enrollment in Phase 1b combination arm of rezatapopt with pembrolizumab due to lack of clinically meaningful benefit.
Enrollment commenced in investigator-initiated Phase 1b study of rezatapopt in relapsed/refractory AML/MDS with TP53 Y220C mutation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.